Silo Pharma Says EPO Grants Patent Covering Preventative Approach Of Lead Candidate SPC-15, Intranasal, Nose-To-Brain Treatment Targeting PTSD And Stress-Induced Affective Disorders

Patent strengthens global IP protection for novel treatment approach designed to prevent stress-induced psychiatric disorders before symptoms develop

SARASOTA, FLA., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a managed AI agent platform and developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the European Patent Office (EPO) has granted a patent covering the preventative approach of its lead candidate SPC-15, a novel intranasal, nose-to-brain treatment targeting post-traumatic stress disorder (PTSD) and stress-induced affective disorders. The Company has an exclusive license for the European patent from Columbia University.

The granted patent, European Patent No. EP3952852, "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress," covers methods of preventing stress-induced fear, depressive-like behavior and associated affective disorders by administering selected serotonin 4 (5-HT4) receptor agonists ahead of a stressor such as potential extreme stress exposure.